Table 1.
Clinical, and endoscopic characteristics of cirrhotic and control patients
| Characteristic | Cirrhotic Patients (n = 31) | Control Patients (n = 29) | p value |
|---|---|---|---|
| Prior variceal bleeding, n (%) | 5 (16.1%) | NA | |
| Prior EIS/EVL, n (%) | 8 (25.8%) | NA | |
| Underlying hepatic pathology, n (%): | |||
| HCV | 8 (25.8%) | NA | |
| HCC | 20 (64.5%) | ||
| Others | 3 (9.7%) | ||
| Child-Pugh class, n (%): | |||
| A | 20 (64.5%) | NA | |
| B | 10 (32.3%) | ||
| C | 1 (3.2%) | ||
| TE score, mean ± SD | 26 ± 12.4 | 6.8 ± 1.4 | <0.001* |
| EGD findings: | |||
| Esophageal varices, n (%) | |||
| Presence | 26 (83.9%) | NA | |
| Large EV | 8 (25.8%) | ||
| Gastric varices, n (%) | 16 (51.6%) | ||
| PHG, n (%) | 20 (64.5%) | ||
| Capsule endoscopic findings: | |||
| Prevalence, n (%) | 21 (67.7%) | 2 (6.9%) | <0.001* |
| SB mucosal lesions; n (%) | |||
| 1—Red spots | 17 (54.8%) | 1 (3.4%) | <0.001* |
| 2—Angioectasias | 16 (51.6%) | 0 | <0.001* |
| 3—Inflammatory like lesions | 13 (41.9%) | 1 (3.4%) | <0.001* |
| 4—Varices | 5 (16.1%) | 0 | 0.024* |
* p<0.05 was considered statistically significant. EIS, endoscopic injection sclerotherapthy; EVL, endoscopic variceal ligation; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; TE, transient elastography; EGD, esophagogastroduodenoscopy; EV, esophageal varices; PHG, portal hypertensive gastropathy; SB, small bowel; NA, non applicable.